Angstrom6 is effective at blocking the migration of the OVCAR8, OVCAR3, ES2, IGROV-1, MDA-MB-468, and MDA-MB361 cells with IC₅₀s in the range of 10 to 100 nM^[3] .
Angstrom6 potentiates the CD44-dependent adhesion of cancer cells to hyaluronic acid and activated CD44-mediated signaling, as evidenced by focal adhesion kinase and MAP/ERK kinase phosphorylation^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Angstrom6 (100 mg/kg; s.c. twice daily) reduces the number of lung foci generated by the i.v. injection of B16-F10 melanoma cells by 50%^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:C57Bl/6 mice (bearing B16-F10 cells)[3]Dosage:100 mg/kgAdministration:S.c.; twice a day for 11 daysResult:Reduced the number of lung nodules and reduced the number of lung metastases to 50% of control.

910.97

C??H??N??O??

220334-14-5

Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-NH2

Ac-KPSSPPEE-NH2

Room temperature in continental US; may vary elsewhere.

Powder-80°C2 years-20°C1 yearIn solvent-80°C6 months-20°C1 month

• [1]. Ghamande SA, et al. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008;111(1):89-94.

  [2]. Finlayson M. Modulation of CD44 Activity by A6-Peptide. Front Immunol. 2015;6:135. Published 2015 Mar 30.

  [3]. Piotrowicz RS, et al. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol Cancer Ther. 2011;10(11):2072-2082.